Creative Planning Has $6.67 Million Stock Position in Agilent Technologies, Inc. (NYSE:A)

Creative Planning grew its stake in Agilent Technologies, Inc. (NYSE:A) by 5.9% during the 3rd quarter, HoldingsChannel reports. The firm owned 44,910 shares of the medical research company’s stock after acquiring an additional 2,498 shares during the quarter. Creative Planning’s holdings in Agilent Technologies were worth $6,668,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of A. Wesbanco Bank Inc. boosted its stake in Agilent Technologies by 8.4% in the 3rd quarter. Wesbanco Bank Inc. now owns 2,455 shares of the medical research company’s stock valued at $365,000 after buying an additional 190 shares in the last quarter. Gibson Capital LLC bought a new position in shares of Agilent Technologies during the third quarter valued at $192,000. InTrack Investment Management Inc acquired a new stake in shares of Agilent Technologies in the 3rd quarter valued at $212,000. Guinness Asset Management LTD grew its holdings in shares of Agilent Technologies by 6.1% in the 3rd quarter. Guinness Asset Management LTD now owns 3,892 shares of the medical research company’s stock worth $578,000 after purchasing an additional 223 shares during the last quarter. Finally, Livforsakringsbolaget Skandia Omsesidigt increased its position in shares of Agilent Technologies by 82.9% during the 3rd quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 7,351 shares of the medical research company’s stock worth $1,091,000 after purchasing an additional 3,331 shares in the last quarter. 87.42% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Agilent Technologies

In related news, CEO Padraig Mcdonnell sold 1,958 shares of the stock in a transaction that occurred on Thursday, August 22nd. The shares were sold at an average price of $145.00, for a total value of $283,910.00. Following the sale, the chief executive officer now directly owns 24,118 shares in the company, valued at $3,497,110. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. In related news, CEO Padraig Mcdonnell sold 1,958 shares of the company’s stock in a transaction on Thursday, August 22nd. The shares were sold at an average price of $145.00, for a total value of $283,910.00. Following the completion of the sale, the chief executive officer now owns 24,118 shares in the company, valued at $3,497,110. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Dominique Grau sold 9,990 shares of Agilent Technologies stock in a transaction dated Thursday, September 26th. The stock was sold at an average price of $145.00, for a total value of $1,448,550.00. Following the transaction, the senior vice president now owns 40,011 shares in the company, valued at approximately $5,801,595. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 13,953 shares of company stock valued at $2,013,630. 0.33% of the stock is currently owned by company insiders.

Agilent Technologies Stock Performance

Agilent Technologies stock opened at $133.03 on Thursday. The company has a market cap of $38.81 billion, a PE ratio of 31.45, a PEG ratio of 6.96 and a beta of 1.05. The company has a current ratio of 1.78, a quick ratio of 1.37 and a debt-to-equity ratio of 0.36. Agilent Technologies, Inc. has a 1 year low of $96.80 and a 1 year high of $155.35. The company’s 50-day moving average is $140.91 and its two-hundred day moving average is $138.59.

Agilent Technologies (NYSE:A) last announced its quarterly earnings data on Wednesday, August 21st. The medical research company reported $1.32 earnings per share for the quarter, beating the consensus estimate of $1.26 by $0.06. Agilent Technologies had a net margin of 21.75% and a return on equity of 25.26%. The business had revenue of $1.58 billion for the quarter, compared to analyst estimates of $1.56 billion. During the same period in the prior year, the business posted $1.43 earnings per share. Agilent Technologies’s revenue was down 5.6% compared to the same quarter last year. Equities analysts anticipate that Agilent Technologies, Inc. will post 5.24 earnings per share for the current year.

Agilent Technologies Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, October 23rd. Investors of record on Tuesday, October 1st were issued a $0.236 dividend. The ex-dividend date of this dividend was Tuesday, October 1st. This represents a $0.94 dividend on an annualized basis and a yield of 0.71%. Agilent Technologies’s dividend payout ratio is presently 22.22%.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the stock. Barclays upped their price objective on shares of Agilent Technologies from $135.00 to $145.00 and gave the stock an “underweight” rating in a research note on Tuesday, October 15th. Citigroup increased their price target on Agilent Technologies from $150.00 to $165.00 and gave the stock a “buy” rating in a research report on Thursday, August 22nd. Evercore ISI lifted their price objective on Agilent Technologies from $135.00 to $145.00 and gave the company an “in-line” rating in a research report on Tuesday, October 1st. TD Cowen increased their target price on Agilent Technologies from $153.00 to $160.00 and gave the stock a “buy” rating in a report on Thursday, August 22nd. Finally, Wolfe Research cut Agilent Technologies from an “outperform” rating to a “peer perform” rating in a report on Thursday, June 27th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $144.36.

Agilent Technologies Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.